ValiRx Regulatory News (VAL)

12 Dec 2007 11:08

Physiomics PLC12 December 2007 Physiomics plc The following announcement was released earlier today, 12 December 2007, byValiRx Plc. For further information: Physiomics plcChristophe Chassagnole01865 784 982 Grant Thornton Corporate FinancePhilip Secrett/Colin Aaronson020 7383 5100 ValiRx Plc ("ValiRx" or "the Company") Physiomics Collaboration Update - Cancer Cell Death Model Developed ValiRx (AIM: VAL), the cancer therapeutics company, today announces that Phase 1of its collaboration with Physiomics plc ("Physiomics") (AIM: PYC), the Europeansystems biology simulation company, has been completed. Under the collaboration, originally announced in February 2007, Physiomics' InSilico simulation technology has been successfully coupled with ValiRx's GeneICEtechnology to generate a cancer cell death model - the Apoptosis Model. This model, on which ValiRx believes it should be able to secure a patent, willbe used to accelerate ValiRx's own internal development programmes and as an R&Dtool to be licensed out to third parties. Already the Apoptosis Model has helped the Company reach key decisions regardingGeneICE in relation to which new cancer cells to target. For example, it hashelped support the decision to focus on specific hormone resistant cancers. Dr Satu Vainikka, CEO of ValiRx, commented: "Systems based biology is able not only to accelerate the R&D process but alsoimprove diagnostic and prognostic processes. We believe our Apoptosis Modelrepresents a significant new tool for use within the pharmaceutical industry andhas already received significant industry interest." Dr Christophe Chassagnole, COO of Physiomics added: "We are pleased to have successfully applied our simulation technology toaccelerate the development of ValiRx's breakthrough GeneICE compounds. Therespective strengths of our technologies have synergised to produce significantgains and we look forward to continuing to work with ValiRx in the future." ---Ends--- About ValiRx plc ValiRx is a biopharmaceutical development company that is building a portfolioof complementary cancer-related therapeutic and diagnostic technologies. Itcurrently holds a worldwide exclusive license for Nucleosomics, the early stageoncology diagnostics technology, and has majority stakes in Cronos Ltd andValiBIO SA: • Cronos holds worldwide exclusive licenses to two innovative and potentially market changing technologies, GeneICE and HyperGenomics, and is developing further novel cancer therapies; • ValiBIO SA is a Belgium joint venture between ValiRx and Bio.Be focusing on the development and commercialisation of products in the epigenomics sector, the first products to be put into development being HyperGenomics and Nucleosomics. ValiRx has a 77% majority holding in the company. ValiRx is headquartered in London, England. Further information can be found atwww.valirx.com About Physiomics plc Physiomics plc (AIM:PYC) is a computational systems biology services companyapplying simulations of cell behaviour to drug development to reduce the highattrition rates of clinical trials. As 80-90 per cent of all clinical drugcandidates fail to reach the market, estimates1 show that an overall ten percent improvement in success rates could reduce the cost of one drug'sdevelopment by as much as $242 million, from the current estimate of around $800million. Physiomics develops computational systems biology models to predict andunderstand cancer drug efficacy from pre-clinical research to clinicaldevelopment. Physiomics has created detailed mathematical models incorporatingmost important molecular events taking place during the human cell cycle andapoptosis processes. Physiomics developed SystemCell(R) technology, amulti-cellular environment software, which enables the simulation of populationof "virtual cells". Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in2004. For further information, please visit www.physiomics-plc.com SystemCell(R) is a registered trademark of Physiomics plc1 Tufts Centre Impact Report 2002 Contact Details: ValiRx Plc WH Ireland GTH Communications Dr Satu Vainikka David Youngman Toby Hall / Jade Mamarbachi+44 (0) 203 008 4416 +44 (0) 161 832 2174 +44 (0) 20 7153 8035 This information is provided by RNS The company news service from the London Stock Exchange